Search results
Showing results for
Malaria is a leading cause of death and illness around the world. Over 200 million cases are reported every year, and more than 400 000 people die. More than 90% of cases are reported in sub-Saharan Africa. Scientists have spent decades searching for an effective vaccine. Hence the recent excitement when Malawi’s government announced it had launched a pilot programme for the world’s first malaria vaccine, RTS,S (also known as Mosquirix©), produced by the pharmaceutical company, GSK. It’s the first vaccine to demonstrate significant reduction in malaria in children. The Conversation Africa’s Ina Skosana asked immunologist Faith Osier about RTS,S.
Rachel Hounsell
Rachel Hounsell - Senior Researcher and Teaching Fellow
Proochista Ariana
- MSc IHTM Executive Team
- MSc IHTM Lecturers
- MSc IHTM advisory committee
- MSc MGH Lecturers
- Principal Investigators
- Research Scientists
Proochista Ariana - Associate Professor
Wirichada Pan-ngum
Wirichada Pan-ngum - Associate Professor
Kevin Marsh
Kevin Marsh - Professor of Tropical Medicine
Marco Liverani
Marco Liverani - Honorary Visiting Research Fellow in Tropical Medicine
Philippe Guérin
Philippe Guérin - Professor of Epidemiology and Global Health
Christiane Dolecek
MD PHD FRCP Christiane Dolecek - Professor of Global Health
Louise Thwaites
BSc MBBS MRCP MD DMSMed MLCOM Louise Thwaites - Professor of Experimental Critical Care
Phaik Yeong Cheah
Phaik Yeong Cheah - Professor of Global Health
Evelyne Kestelyn
Evelyne Kestelyn - Head of the Clinical Trials Unit
Bridget Wills
Bridget Wills - Professor of Tropical Medicine